Literature DB >> 9298735

Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?

B Grinde1, K Stene-Johansen, B Sharma, T Hoel, M Jensenius, K Skaug.   

Abstract

An epidemic of hepatitis A virus (HAV) among intravenous drug abusers in Oslo involved 144 serologically confirmed cases. Another 26 patients (non-drug abusers), of whom 14 were derived from a single nosocomial outbreak, were associated with the epidemic. Sequencing of the VP1/P2A junction revealed that viruses associated with the epidemic were completely identical, whereas other HAV samples collected during the same period differed by up to 10%. HAV was detected in the serum of 48 of 100 patients by a nested PCR. Viremia was observed as early as 25 days before the onset of clinical hepatitis, and up to 30 days after. The large number of patients within the drug abuser group, and the few secondary cases, raised the question of whether the virus could be transmitted by the use of needles. To establish whether viral contamination of drugs did contribute appreciably to maintaining the epidemic, we examined heroin and amphetamine confiscated during the period, using immunomagnetic separation coupled to nested PCR, but failed to detect any virus. Antibodies against hepatitis B virus and hepatitis C virus were common among the HAV infected drug abusers (43% and 81%, respectively), suggesting widespread sharing of needles. This observation and the large number of patients with a demonstrable viremia suggest that needle sharing may contribute to the dissemination of HAV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9298735     DOI: 10.1002/(sici)1096-9071(199709)53:1<69::aid-jmv12>3.0.co;2-s

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

Review 1.  Diagnosis of hepatitis a virus infection: a molecular approach.

Authors:  Omana V Nainan; Guoliang Xia; Gilberto Vaughan; Harold S Margolis
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Surveillance study of hepatitis A virus RNA on fig and date samples.

Authors:  Ingeborg L A Boxman; Nathalie A J M te Loeke; Kyara Klunder; Geke Hägele; Claudia C C Jansen
Journal:  Appl Environ Microbiol       Date:  2011-12-02       Impact factor: 4.792

Review 3.  Sexual transmission and prevention of the hepatitis viruses A-E and G.

Authors:  M G Brook
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

4.  Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002.

Authors:  Miriam Gerlich; Patrick Gschwend; Ambros Uchtenhagen; Alexander Krämer; Jürgen Rehm
Journal:  Eur J Epidemiol       Date:  2006-07-21       Impact factor: 8.082

Review 5.  Hepatitis A: old and new.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

Review 6.  Sexually acquired hepatitis.

Authors:  M G Brook
Journal:  Sex Transm Infect       Date:  2002-08       Impact factor: 3.519

Review 7.  Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review.

Authors:  Kuan-Yin Lin; Guan-Jhou Chen; Yu-Lin Lee; Yi-Chia Huang; Aristine Cheng; Hsin-Yun Sun; Sui-Yuan Chang; Chun-Eng Liu; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

8.  Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks.

Authors:  Tetyana I Vasylyeva; Pavlo Smyrnov; Steffanie Strathdee; Samuel R Friedman
Journal:  J Int AIDS Soc       Date:  2020-07       Impact factor: 5.396

9.  Successful Use of Advertisement Pictures to Assist Recall in a Food-Borne Hepatitis A Outbreak in The Netherlands, 2017.

Authors:  Madelief Mollers; Ingeborg L A Boxman; Harry Vennema; Ife A Slegers-Fitz-James; Diederik Brandwagt; Ingrid H Friesema; Jenny S Batstra; Margreet J M Te Wierik
Journal:  Food Environ Virol       Date:  2018-05-04       Impact factor: 2.778

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.